隨著肥胖問題日益嚴重，藥物輔助減重成為許多人的選擇。Saxenda 秀身達、Ozempic 胰妥讚 與 Mounjaro 猛健樂 皆屬於GLP-1受體激動劑類藥物，但在成分、機制、使用方式及效果上各有差異。本文將深入比較三者的特點，幫助您選擇最適合自己的減重方案。
As the issue of obesity becomes increasingly serious, medication-assisted weight loss has become a choice for many. Saxenda, Ozempic, and Mounjaro are all GLP-1 receptor agonists, but they differ in ingredients, mechanisms, usage, and effectiveness. This article will provide an in-depth comparison of the three, helping you choose the weight loss plan that is best suited for you.
目錄
藥物成分與作用機制
GLP-1受體激動劑類藥物是模仿人體內一種名為胰高血糖素樣肽-1（Glucagon-like peptide-1，簡稱GLP-1）的腸泌素（incretin）所設計的藥物。GLP-1由腸道內分泌細胞及腦幹神經元在進食後分泌，能調節血糖及食慾，對維持體內能量平衡扮演重要角色。
這類藥物的作用機制主要包括：
- 促進胰島素分泌：GLP-1受體激動劑能刺激胰臟β細胞在血糖升高時分泌胰島素，幫助降低血糖。
- 抑制胰高血糖素分泌：同時抑制胰臟α細胞分泌胰高血糖素，減少肝臟產生葡萄糖，有助穩定血糖。
- 延緩胃排空：減緩胃內容物排空速度，延長飽足感，降低進食量。
- 抑制食慾中樞：作用於大腦下視丘，增加飽足感，減少食慾，幫助控制體重。
- 改善胰島素敏感性：部分GLP-1受體激動劑（如Mounjaro）還結合其他激素作用，提升身體對胰島素的反應。
綜合以上作用，GLP-1受體激動劑不僅能有效控制第二型糖尿病患者的血糖，還能顯著減少食量與體重，成為現代肥胖與糖尿病治療的重要利器。
Drug Composition and Mechanism of Action
GLP-1 receptor agonists are designed to mimic a hormone in the body known as glucagon-like peptide-1 (GLP-1), which is an incretin. GLP-1 is secreted by enteroendocrine cells in the intestines and neurons in the brainstem after eating; it plays a crucial role in regulating blood sugar levels and appetite, thus maintaining energy balance in the body.
The mechanisms of action for these drugs primarily include:
- Stimulating Insulin Secretion: GLP-1 receptor agonists stimulate pancreatic beta cells to release insulin when blood sugar levels rise, helping to lower blood sugar.
- Inhibiting Glucagon Secretion: They simultaneously inhibit glucagon secretion from pancreatic alpha cells, reducing the liver’s production of glucose, which helps stabilize blood sugar.
- Delaying Gastric Emptying: These medications slow down the rate at which the stomach empties its contents, prolonging the feeling of fullness and reducing food intake.
- Suppressing Appetite Centers: They act on the hypothalamus in the brain to increase satiety and reduce appetite, aiding in weight control.
- Improving Insulin Sensitivity: Some GLP-1 receptor agonists (like Mounjaro) also work in conjunction with other hormones to enhance the body’s response to insulin.
In summary, GLP-1 receptor agonists not only effectively control blood sugar levels in patients with type 2 diabetes but also significantly reduce appetite and body weight, making them essential tools in the modern treatment of obesity and diabetes.
秀身達 Saxenda（Liraglutide）
Saxenda是單一GLP-1受體激動劑，模仿人體內GLP-1激素，作用於大腦控制食慾中樞，減少食量並延長飽足感，同時減緩胃排空速度，幫助控制體重。
- 外號：飽足感小精靈
- 武器：模仿人體GLP-1激素
- 必殺技：
✓ 讓大腦常喊「我飽了」
✓ 讓胃變成「慢速消化機」
✓ 適合想「溫和瘦」的你
Saxenda: The GLP-1 Receptor Agonist
Saxenda is a single GLP-1 receptor agonist that mimics the body’s GLP-1 hormone. It acts on the brain’s appetite control center to reduce food intake and prolong feelings of fullness, while also slowing gastric emptying to help manage weight.
Nickname: The Satiety Sprite
Weapon: Mimics the body’s GLP-1 hormone
Signature Moves:
- ✓ Keeps the brain saying, “I’m full”
- ✓ Turns the stomach into a “slow-digesting machine”
- ✓ Ideal for those looking to “slim down gently”
胰妥讚 Ozempic（Semaglutide）
同屬GLP-1受體激動劑，但半衰期較長，每週注射一次，方便患者使用。除了減重外，Ozempic主要用於2型糖尿病的血糖控制，並有心血管保護效果。
- 外號：一週一次懶人救星
- 隱藏技能：
✓ 控血糖+護心血管二合一
✓ 臨床數據：甩肉10-15%
✓ 糖尿病友的減重好閨蜜
Ozempic: The Long-Acting GLP-1 Receptor Agonist
Ozempic is also a GLP-1 receptor agonist, it has a longer half-life, requiring only weekly injections for patient convenience. In addition to weight loss, Ozempic is primarily used for blood sugar control in type 2 diabetes and offers cardiovascular protection.
However, currently Ozempic is not registered in Hong Kong just yet.
Nickname: The Once-a-Week Lazy Person’s Savior
Hidden Skills:
- ✓ Dual-action: Blood sugar control + Cardiovascular protection
- ✓ Clinical Data: Shed 10-15% of body weight
- ✓ A great weight loss companion for those with diabetes
猛健樂 Mounjaro（Tirzepatide）
最新一代雙重受體激動劑，結合GLP-1與GIP（葡萄糖依賴性胰島素促泌多肽）雙重機制，不僅抑制食慾、延長飽足感，還能提升胰島素敏感性，促進代謝，有助於更顯著的體重減輕。
- 外號：減重界黑科技
- 炫酷設定：
✓ GLP-1+GIP雙激素聯手
✓ 72週平均減重20%（驚！）
✓ 適合追求「變身效果」的你
Mounjaro: The Next-Generation Dual Receptor Agonist
Mounjaro is the latest generation of dual receptor agonists that combines GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) mechanisms. It not only suppresses appetite and prolongs feelings of fullness but also enhances insulin sensitivity and boosts metabolism, leading to more significant weight loss.
Nickname: The Black Technology of Weight Loss
Cool Features:
- ✓ GLP-1 + GIP dual hormone synergy
- ✓ Average weight loss of 20% over 72 weeks (Wow!)
- ✓ Ideal for those seeking a “transformation effect”
減肥筆使用方式與頻率
| 藥物 | 使用頻率 | 注射方式 |
| Saxenda 秀身達 | 每日注射 | 皮下注射 |
| Ozempic 胰妥讚 | 每週注射一次 | 皮下注射 |
| Mounjaro 猛健樂 | 每週注射一次 | 皮下注射 |
💡 小提醒：怕打針？Ozempic和Mounjaro的每週一次注射方案可能更適合你！
Usage and Frequency of GLP-1 injection
| Medication | Usage Frequency | Injection Method |
| Saxenda | Daily injection | Subcutaneous injection |
| Ozempic | Once weekly | Subcutaneous injection |
| Mounjaro | Once weekly | Subcutaneous injection |
💡 Tip: If you’re afraid of injections, the once-weekly injection plan of Ozempic and Mounjaro might be more suitable for you!
減重效果比較
- Mounjaro 猛健樂
臨床研究顯示，Mounjaro猛健樂在72週內平均可減少約20%體重，效果顯著優於其他兩者。其雙重激動劑機制使其在食慾控制及代謝改善上更具優勢。 - Ozempic 胰妥讚
研究指出，Ozempic 胰妥讚可幫助患者減輕約10%至15%的體重，且同時改善血糖及心血管風險。 - Saxenda 秀身達
Saxenda的減重效果相對溫和，平均可減少約5%至7%的體重，適合輕中度肥胖患者。
Weight Loss Effectiveness Comparison
- Mounjaro
Clinical studies show that Mounjaro can reduce body weight by an average of about 20% over 72 weeks, significantly outperforming the other two. Its dual-agonist mechanism provides greater advantages in appetite control and metabolic improvement.
- Ozempic
Research indicates that Ozempic helps patients lose approximately 10% to 15% of their body weight, while also improving blood sugar levels and reducing cardiovascular risks.
- Saxenda
Saxenda’s weight loss effects are relatively moderate, with an average reduction of about 5% to 7% of body weight, making it suitable for patients with mild to moderate obesity.
效果擂台賽
- 輕量級：Saxenda（-5~7%）→ 像慢慢調整飲食習慣
- 中量級：Ozempic（-10~15%）→ 堪比嚴格運動計畫
- 重量級：Mounjaro（-20%）→ 直接開啟「整個人小一號」模式
Effectiveness Showdown
Lightweight: Saxenda (-5% to -7%)
→ Like gradually adjusting dietary habits.
Middleweight: Ozempic (-10% to -15%)
→ Comparable to a strict exercise regimen.
Heavyweight: Mounjaro (-20%)
→ Directly activates the “whole size down” mode!
減肥筆常見副作用與安全性
三者均可能引起胃腸道不適，如噁心、嘔吐、腹瀉、便秘等，通常在治療初期較明顯，隨時間可逐漸緩解。
- Saxenda 秀身達
副作用較輕微，少數患者可能出現注射部位反應或過敏。 - Ozempic 胰妥讚
除胃腸道症狀外，少數患者可能有胰腺炎、膽結石風險，需醫師嚴密監控。 - Mounjaro 猛健樂
副作用類似GLP-1類藥物，胃腸不適較常見，且需注意甲狀腺腫瘤及胰腺炎等罕見風險。
Common Side Effects and Safety of GLP-1 injection
All three medications may cause gastrointestinal discomfort, such as nausea, vomiting, diarrhea, and constipation, which are usually more pronounced during the initial treatment phase but tend to alleviate over time.
Saxenda
- Side effects are generally mild; a few patients may experience injection site reactions or allergic reactions.
Ozempic
- In addition to gastrointestinal symptoms, a small number of patients may face risks of pancreatitis or gallstones, requiring close monitoring by a physician.
Mounjaro
- Side effects are similar to other GLP-1 drugs, with gastrointestinal discomfort being common. Additionally, there are rare risks of thyroid tumors and pancreatitis to be aware of.
瘦身筆適用對象與禁忌
- Saxenda 秀身達
適用於BMI≥30的成人肥胖患者，或BMI≥27且有體重相關疾病者。 - Ozempic 胰妥讚
主要用於2型糖尿病患者控制血糖，同時有體重管理需求者。 - Mounjaro 猛健樂
適用於2型糖尿病患者及肥胖或超重且伴有相關疾病的成人。
禁忌包括有甲狀腺髓樣癌病史、嚴重胃腸疾病、胰腺炎等患者。
Suitable Candidates and Contraindications for GLP-1 injection
Saxenda
- Suitable for: Adults with a BMI ≥ 30, or those with a BMI ≥ 27 who have weight-related diseases.
Ozempic
- Mainly used for: Patients with type 2 diabetes who need blood sugar control and have weight management needs.
Mounjaro
- Suitable for: Adults with type 2 diabetes and obesity or overweight conditions with related diseases.
Contraindications:
Patients with a history of medullary thyroid carcinoma, severe gastrointestinal diseases, pancreatitis, and other specific conditions should avoid these medications.
如何選擇適合自己的減肥筆？
選擇時應考慮個人健康狀況、減重目標、使用便利性及副作用承受度。若追求顯著減重效果且能接受每週注射，Mounjaro 猛健樂為首選；若同時需控糖，Ozempic 胰妥讚效果理想；若偏好每日注射且副作用較輕，Saxenda 秀身達為不錯選擇。建議在專業醫師指導下選擇並調整療程。
How to Choose the Right GLP-1 injetion for You
When selecting a GLP-1 injection, consider your personal health status, weight loss goals, convenience of use, and tolerance for side effects.
- If you’re aiming for significant weight loss and can handle weekly injections, Mounjaro is the top choice.
- If you also need to manage blood sugar levels, Ozempic offers ideal effects.
- If you prefer daily injections with milder side effects, Saxenda is a good option.
It’s recommended to choose and adjust your treatment under the guidance of a healthcare professional.
結語
Saxenda、Ozempic與Mounjaro皆為現代有效的減重藥物，三者各有優勢與適用範圍。了解它們的差異與特點，有助您做出符合自身需求的選擇。配合健康飲食與運動，方能達到最佳減重效果與長期維持。
如欲了解更多或預約專業諮詢，歡迎聯絡我們的醫療團隊，為您量身打造專屬減重方案。
Conclusion
Saxenda, Ozempic, and Mounjaro are all effective modern GLP-1 receptor agonist medications, each with its own advantages and suitable applications. Understanding their differences and characteristics can help you make a choice that aligns with your personal needs.
By combining these medications with a healthy diet and exercise, you can achieve optimal weight loss results and maintain them over the long term.
For more information or to schedule a professional consultation, please contact our medical team to create a tailored weight loss plan just for you.
瘦身筆常見問題（FAQ）
1. Saxenda 秀身達、Ozempic 胰妥讚 和 Mounjaro 猛健樂有什麼主要差異？
三者皆屬GLP-1受體激動劑類藥物，但Saxenda需每日注射，適合追求溫和減重者；Ozempic與Mounjaro為每週注射一次，使用更方便。Mounjaro結合GLP-1與GIP雙重機制，減重效果最顯著。
2. 這三種藥物的減重效果分別是多少？
Mounjaro平均可減重約20%，Ozempic約10-15%，Saxenda約5-7%。減重效果會因人而異，需配合飲食與運動。
3. 這些藥物有什麼常見副作用？
主要副作用為胃腸不適，如噁心、嘔吐、腹瀉等，通常在治療初期較明顯，後續會逐漸減輕。Mounjaro需特別注意甲狀腺及胰腺相關罕見風險。
4. 誰適合使用這些減重藥物？
Saxenda適用於BMI≥30或BMI≥27伴有相關疾病的成人；Ozempic和Mounjaro主要用於2型糖尿病患者及肥胖或超重且有相關疾病者。具體用藥需由醫生評估決定。
5. 這些藥物的注射頻率和使用方便度如何？
Saxenda需每日注射，使用頻率較高；Ozempic與Mounjaro為每週注射一次，使用更方便，適合怕打針或生活忙碌者。
6. 這些藥物會影響血糖嗎？
Ozempic和Mounjaro主要用於控制2型糖尿病患者的血糖，同時有減重效果。Saxenda主要用於減重，對血糖控制影響較小。
7. 自己注射會痛嗎？針頭大不大？
這些減肥藥的針頭非常細小，注射時通常只有輕微刺痛或針扎感，疼痛感非常輕微且短暫，多數人都能輕鬆接受。醫護人員也會教導正確注射技巧，讓使用過程更舒適。
8. 停藥後會反彈嗎？如何避免體重反彈？
停用減肥藥後，若沒有持續控制飲食與運動，體重有可能反彈。建議搭配健康飲食與規律運動，養成良好生活習慣，即使停藥也能有效維持體重，減少反彈風險。
9. 如果只想改善局部脂肪，如雙下巴或大腿脂肪，減肥筆適合嗎？
減肥筆主要用於全身性體重管理，對局部脂肪的改善有限。若想針對小範圍脂肪雕塑，建議考慮脂肪溶解注射（如溶脂針）或其他局部塑形療程，效果更佳且針對性強。
詳請可睇：消脂針常見Q&A！溶脂針真的有用嗎？哪款脂針效果比較好？
FAQs on GLP-1 injections
1. What are the main differences between Saxenda, Ozempic, and Mounjaro?
All three medications belong to the GLP-1 receptor agonist class, but Saxenda requires daily injections, making it suitable for those seeking moderate weight loss. Ozempic and Mounjaro are injected weekly, offering more convenience. Mounjaro combines GLP-1 and GIP dual mechanisms, resulting in the most significant weight loss effects.
2. What are the weight loss effects of these medications?
Mounjaro can average about 20% weight loss, Ozempic around 10-15%, and Saxenda approximately 5-7%. Weight loss results can vary by individual and should be accompanied by diet and exercise.
3. What are the common side effects of these medications?
The main side effects include gastrointestinal discomfort, such as nausea, vomiting, and diarrhea, which are usually more pronounced during the initial treatment phase and gradually decrease over time. Mounjaro requires particular attention to rare risks related to the thyroid and pancreas.
4. Who is suitable for using these weight loss medications?
Saxenda is suitable for adults with a BMI ≥ 30 or a BMI ≥ 27 with related health conditions. Ozempic and Mounjaro are primarily used for patients with type 2 diabetes and those who are obese or overweight with related conditions. Specific medication use should be assessed and determined by a physician.
5. What is the injection frequency and convenience of these medications?
Saxenda requires daily injections, which is more frequent. Ozempic and Mounjaro are injected weekly, making them more convenient for those who fear injections or have busy lifestyles.
6. Do these medications affect blood sugar levels?
Ozempic and Mounjaro are primarily used to control blood sugar levels in patients with type 2 diabetes while also aiding in weight loss. Saxenda is mainly used for weight loss and has a lesser impact on blood sugar control.
7. Does self-injection hurt? How big is the needle?
The needles for these weight loss medications are very small, and injections typically cause only a slight sting or pinching sensation. The pain is minimal and brief, and most people find it easy to tolerate. Healthcare providers will also teach proper injection techniques to make the process more comfortable.
8. Will I regain weight after stopping the medication? How can I avoid weight rebound?
After discontinuing the weight loss medication, if dietary and exercise controls are not maintained, weight rebound is possible. It is recommended to combine healthy eating with regular exercise and develop good lifestyle habits to effectively maintain weight and reduce the risk of rebound, even after stopping the medication.
9. If I only want to target specific fat areas, such as a double chin or thigh fat, are GLP-1 medication suitable?
GLP-1 receptor agonsit injections are primarily used for overall weight management and have limited effects on localized fat. If you want to target small areas for fat sculpting, consider fat dissolving injections (like lipolytic injections) or other localized shaping treatments, which may offer better and more targeted results.